fbpx

CyberKnife® Treatment for Prostate Cancer

“I believe this is the way all treatment should be done. I had no fear of what was being done to me. I know everyone is different and I know I was blessed to be here. Thank you to the team for their help and support.” – Charles 59, Prostate Patient

The CyberKnife robotic radiosurgery system is a widely used form of nonsurgical prostate stereotactic body radiation therapy (SBRT). The American Society for Radiation Oncology (ASTRO) believes that enough clinical evidence exists so that SBRT should be considered an appropriate treatment option for select patients with low- to intermediate-risk prostate cancer. CyberKnife is designed to avoid healthy tissue and critical anatomy, therefore reducing side effects such as erectile dysfunction, urinary and bowel complications.

Key Advantages

  • Only 5 Treatments
  • Pinpoint Accuracy
  • Few Side Effects
  • Non-Invasive
  • No Recovery Time

Meet Our Prostate Specialists

dr-bedwinek_suit
John Bedwinek M.D.
SpaceOAR Application Specialist

Board-certified in radiation oncology, John Bedwinek, M.D., is a graduate of Columbia University, did his residency at Dartmouth, and then completed and completed his fellowship at the prestigious University of Texas M.D. Anderson Cancer Center.Dr. Bedwinek has more than 30 years of experience in patient care with a special interest in breast cancer, prostate cancer, and CyberKnife treatment. He has more than 50 publications, both in peer-reviewed journals and book chapters.

He has been on America’s Best Doctors list every year since its inception in 1997. Dr. Bedwinek was also named by Good Housekeeping magazine as one of “America’s Top Breast Cancer Doctors.” He has been awarded fellowships in the American College of Radiology, the College of Radiation Oncology and the American Society of Radiology and Oncology.

Dr. Bedwinek is a certified SpaceOAR Application Specialist. To find out more about SpaceOAR click here.

dr-morris_suit
David Morris M.D.

Board-certified in radiation oncology, David Morris, M.D., received his medical degree from Georgetown University. He completed his internship at the Washington Hospital Center and his radiation oncology residency and fellowship training at the University of North Carolina Hospitals. He served as University of North Carolina’s Cyberknife Program Director, Clinical Division Director, and as a clinical associate professor.

Dr. Morris is the medical director and board member of St. Louis CyberKnife. He has 19 years of experience with radiosurgery and 11 years with CyberKnife treatment, with a particular interest in brain, pituitary, and spine tumors. He has written extensive articles and a book chapter on Cyberknife technology in Youmans’ Neurological Surgery 6th edition titled, Image-Guided Robotic Radiosurgery: The Cyberknife. He previously has been honored as a US News and World Reports “Top Doctor”, Castle Connolly “Top Doctor” and Best Doctor in St. Louis in radiation oncology. He has served as a volunteer for the American Society of Radiation Oncology and the American Board of Radiology.

Prostate Cancer Early Detection

The American Cancer Society (ACS) recommends that men have a chance to make an informed decision with their health care provider about whether to be screened for prostate cancer. The decision should be made after getting information about the uncertainties, risks, and potential benefits of prostate cancer screening. Men should not be screened unless they have received this information. Men who want to be screened should be tested with the prostate-specific antigen (PSA) blood test.

American Cancer Society
Recommended Prostate Cancer Screening Times

  • Age 50 for men who are at average risk of prostate cancer and are expected to live at least 10 more years.
  • Age 45 for men at high risk of developing prostate cancer. This includes African Americans and men who have a first-degree relative (father, brother, or son) diagnosed with prostate cancer at an early age (younger than age 65).
  • Age 40 for men at even higher risk (those with more than one first-degree relative who had prostate cancer at an early age).
VA Choice Program
US Army soldier with US flag at a military parade

St. Louis CyberKnife is now accepting patients through the Veteran's Choice program. Click on the button below to see if you are a candidate.

Speak with one of our dedicated team members about how we can help today.

CyberKnife® Treatment for Prostate Cancer

The CyberKnife robotic radiosurgery system is a widely used form of nonsurgical prostate stereotactic body radiation therapy (SBRT). The American Society for Radiation Oncology (ASTRO) believes that enough clinical evidence exists so that SBRT should be considered an appropriate treatment option for select patients with low- to intermediate-risk prostate cancer. CyberKnife is designed to avoid healthy tissue and critical anatomy, therefore reducing side effects such as erectile dysfunction, urinary and bowel complications.

“I believe this is the way all treatment should be done. I had no fear of what was being done to me. I know everyone is different and I know I was blessed to be here. Thank you to the team for their help and support.” – Charles 59, Prostate Patient

Key Advantages

  • Only 5 Treatments
  • Pinpoint Accuracy
  • Few Side Effects
  • Non-Invasive
  • No Recovery Time

Meet Our Prostate Specialists

dr-bedwinek_suit
John Bedwinek M.D.
SpaceOAR Application Specialist

Board-certified in radiation oncology, John Bedwinek, M.D., is a graduate of Columbia University, did his residency at Dartmouth, and then completed and completed his fellowship at the prestigious University of Texas M.D. Anderson Cancer Center.Dr. Bedwinek has more than 30 years of experience in patient care with a special interest in breast cancer, prostate cancer, and CyberKnife treatment. He has more than 50 publications, both in peer-reviewed journals and book chapters.

He has been on America’s Best Doctors list every year since its inception in 1997. Dr. Bedwinek was also named by Good Housekeeping magazine as one of “America’s Top Breast Cancer Doctors.” He has been awarded fellowships in the American College of Radiology, the College of Radiation Oncology and the American Society of Radiology and Oncology.

Dr. Bedwinek is a certified SpaceOAR Application Specialist. To find out more about SpaceOAR click here.

dr-morris_suit
David Morris M.D.

Board-certified in radiation oncology, David Morris, M.D., received his medical degree from Georgetown University. He completed his internship at the Washington Hospital Center and his radiation oncology residency and fellowship training at the University of North Carolina Hospitals. He served as University of North Carolina’s Cyberknife Program Director, Clinical Division Director, and as a clinical associate professor.

Dr. Morris is the medical director and board member of St. Louis CyberKnife. He has 19 years of experience with radiosurgery and 11 years with CyberKnife treatment, with a particular interest in brain, pituitary, and spine tumors. He has written extensive articles and a book chapter on Cyberknife technology in Youmans’ Neurological Surgery 6th edition titled, Image-Guided Robotic Radiosurgery: The Cyberknife. He previously has been honored as a US News and World Reports “Top Doctor”, Castle Connolly “Top Doctor” and Best Doctor in St. Louis in radiation oncology. He has served as a volunteer for the American Society of Radiation Oncology and the American Board of Radiology.

Prostate Cancer Early Detection

The American Cancer Society (ACS) recommends that men have a chance to make an informed decision with their health care provider about whether to be screened for prostate cancer. The decision should be made after getting information about the uncertainties, risks, and potential benefits of prostate cancer screening. Men should not be screened unless they have received this information. Men who want to be screened should be tested with the prostate-specific antigen (PSA) blood test.

American Cancer Society
Recommended Prostate Cancer Screening Times

  • Age 50 for men who are at average risk of prostate cancer and are expected to live at least 10 more years.
  • Age 45 for men at high risk of developing prostate cancer. This includes African Americans and men who have a first-degree relative (father, brother, or son) diagnosed with prostate cancer at an early age (younger than age 65).
  • Age 40 for men at even higher risk (those with more than one first-degree relative who had prostate cancer at an early age).

Speak with one of our dedicated team members about how we can help today.

VA Choice Program
US Army soldier with US flag at a military parade

St. Louis CyberKnife is now accepting patients through the Veteran's Choice program. Click on the button below to see if you are a candidate.